Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:pathogenesis:microbiota:interaction [05.19.2020] – [Coronavirus] sallieqhome:pathogenesis:microbiota:interaction [05.23.2020] – [Coronavirus] sallieq
Line 52: Line 52:
 chloroquine (({{pubmed>long:    32147496}})) chloroquine (({{pubmed>long:    32147496}}))
  
- neuroinvasive potential(({{pubmed>long:    32104915}}))+neuroinvasive potential(({{pubmed>long:    32104915}}))
  
 Unique epidemiological and clinical features(({{pubmed>long:    32134116}})) Unique epidemiological and clinical features(({{pubmed>long:    32134116}}))
Line 70: Line 70:
 February 2020 The multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine. (({{pubmed>long:32075365}}))  February 2020 The multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine. (({{pubmed>long:32075365}})) 
  
-Drug used for Ebola is being tested on 600 participants in a study started March 15, 2020 and expected to complete in May 2020 [[https://www.clinicaltrials.gov/ct2/show/NCT04292730|Treatment study]]+**May 2020** Results of extensive study of [[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext|hydroxychloroquine and chloroquine]] indicate harm rather than help from use of these drugs in coronavirus cases. 
 + 
 +96 032 patients (mean age 53·8 years, 46·3% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria.  
 + 
 +Data from 671 hospitals in six continents  included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2.  
 + 
 +Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded.  
 + 
 +After controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity),  
 + 
 +The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).  
 + 
 +Compared with the control group (0·3%), hydroxychloroquine (6·1%; 2·369, 1·935–2·900), hydroxychloroquine with a macrolide (8·1%; 5·106, 4·106–5·983), chloroquine (4·3%; 3·561, 2·760–4·596), and chloroquine with a macrolide (6·5%; 4·011, 3·344–4·812) were independently associated with an increased risk of de-novo ventricular arrhythmia during hospitalisation.  
 + 
 + 
 +When compared with mortality in the control group (9·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·223–1·457), hydroxychloroquine with a macrolide (23·8%; 1·447, 1·368–1·531), chloroquine (16·4%; 1·365, 1·218–1·531), and chloroquine with a macrolide (22·2%; 1·368, 1·273–1·469) were each independently associated with an increased risk of in-hospital mortality.  
  
 [[https://www.jbc.org/content/early/2020/04/13/jbc.RA120.013679.abstract|Remdesivir believed to inhibit RNA synthesis in virus and coronavirus]] [[https://www.jbc.org/content/early/2020/04/13/jbc.RA120.013679.abstract|Remdesivir believed to inhibit RNA synthesis in virus and coronavirus]]
  
 [[https://www.mediterranee-infection.com/azithromycin-and-ciprofloxacin-have-a-chloroquine-like-effect-on-respiratory-epithelial-cells/|Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells]] [[https://www.mediterranee-infection.com/azithromycin-and-ciprofloxacin-have-a-chloroquine-like-effect-on-respiratory-epithelial-cells/|Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells]]
 +
 +Drug used for Ebola is being tested on 600 participants in a study started March 15, 2020 and expected to complete in May 2020 [[https://www.clinicaltrials.gov/ct2/show/NCT04292730|Treatment study]]
 +
    
 [[https://www.monash.edu/discovery-institute/news-and-events/news/2020-articles/Lab-experiments-show-anti-parasitic-drug,-Ivermectin,-eliminates-SARS-CoV-2-in-cells-in-48-hours [[https://www.monash.edu/discovery-institute/news-and-events/news/2020-articles/Lab-experiments-show-anti-parasitic-drug,-Ivermectin,-eliminates-SARS-CoV-2-in-cells-in-48-hours
home/pathogenesis/microbiota/interaction.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.